Max Healthcare Q2 FY27 Earnings Call: Revenue Rises 20% YoY, Rs. 415 Cr Brownfield Expansion Approved (MAXHEALTH)

Max Healthcare Institute Ltd held its Q2 FY27 earnings call on October 30, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.

Double-digit growth with flat margins despite capacity surge

• Revenue Rs.3,219 Cr (+20% YoY) — vs Rs.2,692 Cr in Q2 FY26 and Rs.2,982 Cr in Q1 FY27; operating EBITDA Rs.820 Cr (+18% YoY, +16% QoQ) and PAT Rs.448 Cr (+10% YoY, normalised for a Rs.149 Cr one-time tax gain; +26% QoQ vs Rs.357 Cr in Q1 FY27).
• EBITDA margin 26.8% — flat YoY despite a 14% YoY increase in operational bed capacity and ~200 bps above the trailing quarter; occupancy steady at 77% YoY, occupied bed days +13% YoY, ARPP Rs.2.31 lakh (+8% YoY), EBITDA per bed Rs.77 lakh p.a. (+4% YoY).
• H1 FY27 gross revenue Rs.6,200 Cr (+18% YoY) — operating EBITDA Rs.1,524 Cr (+17% YoY) at 25.9% margin (flat vs H1 FY26); PAT Rs.805 Cr vs Rs.750 Cr (+7% YoY, normalised); bed capacity ~6,200 (+20% YoY).
• Free cash flow Rs.500 Cr in Q2 — Rs.292 Cr invested in expansion and Rs.195 Cr disbursed as dividend; net debt Rs.2,369 Cr with net debt/EBITDA below 1x.
• Growth mix: ~12-13% patient volume growth — underpinning the 20% Q2 FY27 revenue growth; the realization contribution was not separately quantified on the call.
• Saket ramp-up drag — newly commissioned 260 beds at MAX Smart broke even within 3 months and run at high occupancy, but initial ramp-up dragged Saket complex EBITDA; excluding Saket, revenue grew 20% and EBITDA 25% YoY. Management guided a return to normalcy by Q3 FY 2026-2027.

Brownfield momentum plus a multi-year greenfield runway

• Board approved Rs.415 Cr for 209 brownfield beds — at MAX Noida, MAX Vaishali and BLK MAX (part of a Rs.450 Cr outlay), plus an MLCP tower at BLK costing ~Rs.85 Cr; most of this capacity expected over the 18-24 months following Q2 FY 2026-2027.
• 202 brownfield beds added in Q2 FY27 — mainly MAX Smart, MAX Lucknow, MAX Noida and MAX Dwarka; services commenced at the new MAX Dwarka oncology block, enabling ~20 beds in Q3 FY27.
• Near-term pipeline — balance 205 beds at MAX Nanavati and MAX Smart Saket post Diwali Puja (Q3 FY 2026-2027); 100 beds at MAX Lucknow in H2 FY 2026-2027; 85 beds at MAX Noida by December 2027 (Q3 FY 2027-2028); 500 beds at Sector 56 Gurgaon with phase commissioning expected by end of FY 2026-2027; 250 beds at Bhubaneswar phased over 12-15 months from Q2 FY 2026-2027.
• December 2027 / FY 2029 pipeline — 100 beds at MAX Nagpur and 400 beds at Zirakpur Mohali on track for December 2027 (Q3 FY 2027-2028); 200 beds at Pritampura expected in FY 2029; 400 beds at Patparganj expected by end of FY 2029.
• FY30 pipeline — 260 beds at MAX Dwarka, 270 beds (Nanavati phase 2), 450 beds at Pune (IOD received), 200 beds (Vaishali new tower) and 400 beds (Shahid Path, Lucknow phase 1) all expected by FY30; Lucknow phase 1 is awaiting formal environmental clearance and building plans before construction commences.
• Noida site optionality — the 18-acre Noida site has ~378-380 of 504-505 beds activated as of Q2 FY 2026-2027, with 85 beds being added on brownfield basis due to high utilization; the residual 11 acres can accommodate an additional 700 beds as a separate phase (period unspecified). Greater Noida holds only a land parcel earmarked for 400 beds (period unspecified).

De-empanelment strategy and the chemo discontinuation drag

• Rs.100 Cr annual FY 2026-2027 impact from chemo discontinuation — management reiterated the margin drag from discontinuing select high-value chemotherapy drugs for institutional patients following CGHS rate revisions; oncology's share of inpatient revenue fell to 21% from 26% in Q2 FY26.
• Rs.200 Cr net gain from CGHS price revision — Abhay Soi stressed the CGHS gain and the oncology loss must be viewed together — "you can't take one without the other."
• Ex-oncology growth of 25% YoY in Q2 FY27 — with ex-oncology ARPP up 11% YoY; Q2 FY27 EBITDA margin was flat YoY despite oncology revenue exiting the books, and Abhay Soi indicated ex-oncology EBITDA growth would be higher. Keshav Gupta declined to impute a specific ex-oncology EBITDA value not present in the P&L.
• De-empanelment sequence — BLK de-empanelled in May 2026 (FY 2026-2027), followed by CGHS, Railways (cited as non-paying) and ECHS at Shalimar Bagh; further calls will be taken at individual hospital level. Mature hospitals de-empanel to distil payer mix while newer hospitals take on institutional business.
• CGHS/institutional channel at ~18.5% of Q2 FY27 revenue — down ~300 bps YoY; management stated there is no intention to reduce exposure to the institutional channel and will not target a fixed share for it.
• Cardiology revenue grew just under 18% YoY in Q2 FY27 — Abhay Soi noted cardiology is typically seasonal, with winter bringing higher cardiology incidence and lower orthopedic incidence.

Trade margin cap unquantified; drug pricing matter sub judice

• Government imposed a rate margin cap on non-scheduled drugs — management said it is still working out the impact on sales and EBITDA; no quantification was provided on the call.
• Chemotherapy is generally 30% of overall oncology revenue — within chemo, ORC and monopoly drugs will not be impacted by the price cap, along with generic drugs; assessment is possible only once revised MRPs are received. Management did not disclose pharmacy's share of revenue or EBITDA.
• CGHS impact already in the run-rate — Abhay Soi noted the CGHS impact on oncology already happened in FY 2026-2027 and is coming through in the quarters, so it will not be an additional factor in the trade margin cap assessment.
• Drug/devices/consumables pricing matter is sub judice — including the onco margin cap, which management is still assessing; management urged reliance on court pleadings rather than media coverage.
• Hospital sector's court position — per management, the sector's position is that "median net profit for the entire sector was ~9% in Q2 FY 2026-2027" for a capital-intensive industry, and the industry, historically product-based rather than services-based in pricing, may "possibly" need to recalibrate going forward (period unspecified).

Quantified EBITDA drags and clinician retention confidence

• Rs.40-50 Cr guided initial EBITDA loss at Sector 56 Gurgaon — facility expected online by end of FY 2026-2027; management will open with 150-200 beds rather than all 500 phase-one beds on day one, referencing the Dwarka playbook (300 beds, Rs.30 Cr EBITDA loss, break-even in six months with Rs.30-35 Cr cumulative peak loss — "the answer will be somewhere there"). No direct duration answer was given on whether the drag persists across FY 2027-2028.
• Mohali greenfield drag "lower, much lower" — roughly Rs.30 Cr in FY 2028-2029 — management stressed this is only a "line in the sand" estimate; with opening slated for December of FY 2027-2028, clinician teams have not yet been onboarded and precise numbers will only be known once onboarding begins.
• Clinician attrition up to ~1% per year — with 14 facilities in Delhi NCR and over 4,000 full-time clinicians as of Q2 FY 2026-2027, Abhay Soi said ongoing NCR expansion provides career progression for second-line talent; without adding hospitals, the next line of clinicians would join competition.
• Gurugram competition — a competitor recently commercialized a new hospital in Gurugram, but management noted no meaningful star-doctor attrition has been seen in the market.
• CGHS empanelment terms — a 6-month evergreen agreement renewed every 6 months, with either side able to disempanel on 1-month notice; the new Gurugram facility will seek CGHS and ECHS empanelment.

Growth acceleration expected in H2 FY27; adjacencies positioned as future stars

• Top-line growth expected to accelerate in Q3-Q4 FY 2026-2027 — from the ~20% delivered in Q2 FY27, as the chemo discontinuation impact (which began in Q3 FY 2025-2026) anniversaries in Q3 FY 2026-2027, aided by the lower base and incremental brownfield/greenfield additions coming on stream.
• MAX at Home revenue Rs.86 Cr (+37% YoY) — 16 service lines across 15 cities with >56% repeat transactions; MAX Lab revenue Rs.66 Cr (+24% YoY) across 60+ cities serving >7 lakh patients. Both remain relatively small contributors to group revenue.
• Historical 20-25% CAGR at MAXLAB and MAXATHome — with typical quarter-to-quarter variation of ±4-5 percentage points; their group revenue share has stayed static only because core businesses have also grown ~25-26% over the last 5 years.
• Management views both as "stars of the future" — continuing to invest, with both already quite profitable; management did not commit to the 3-5 year horizon the analyst asked about for them becoming meaningful contributors.
• Bhubaneswar renovation — 80 beds shut for ~12 months, first-phase delivery of a few OTs and beds expected in about 3 months (~Q4 FY 2026-2027); a further 250-bed tower to be added over the next 2-3 years (by FY 2029-2030). Q2 FY27 revenue was Rs.38 Cr with EBITDA of Rs.4 Cr; Kalinga Hospital shareholding rose to 66% post rights issue.
• International & digital momentum — international patient revenue Rs.307 Cr (+33% YoY), now 10% of hospital healthcare revenues; digital revenue Rs.1,099 Cr (~34% of overall revenue); website traffic crossed 1.14 crore sessions (+44% YoY). Free treatment was provided to over 57,000 EWS patients worth Rs.90 Cr at tariff (+47% YoY).